The global pulmonary function testing market is anticipated to grow at a considerable CAGR of 8.3% during the forecast period. Increasing incidences of lung-related disorders and the numerous advantages offered by pulmonary function testing positively impact the market growth. According to the British Lung Association Foundation 2023 report, nearly 10,000 people in the UK are diagnosed with lung diseases every week. Additionally, pulmonary diseases accounted for more than 70,00,000 hospitals admission with 6 million inpatient bed-days in the UK annually. Pulmonary function texting is an ideal tool for assessing the physiological impact of a virus that largely attacks the cardiopulmonary system. Additionally, new product development, launches, and technological advancements offered by public and private organizations in the testing kit further fueled the market growth.
Browse the full report description of “Pulmonary Function Testing Market Size, Share & Trends Analysis Report by Device Type (Handheld, and Tabletop), by Product Type (Spirometry, Lung Volume Testing, Arterial Blood Gas Testing, Pulse Oximetey, and Others (Maximal Voluntary Ventilation)), by Application (Respiratory Infections, Asthma, Asbestosis, Tumors, Sarcoidosis, and Others (chest surgery), and by End User (Hospitals, Clinical Laboratories, and Diagnostics Laboratories) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/pulmonary-function-testing-market
• In October 2021, a novel artificial intelligence blood testing technology developed by researchers at the Johns Hopkins Kimmel Cancer Center was found to detect over 90% of lung cancers in samples from nearly 800 individuals with and without cancer. The test approach, called DELFI (DNA evaluation of fragments for early interception), spots unique patterns in the fragmentation of DNA shed from cancer cells circulating in the bloodstream. Applying this technology to blood samples taken from 796 individuals in Denmark, the Netherlands and the US investigators unveiled that the DELFI approach accurately distinguished between patients with and without lung cancer.
• In March 2022, KoKo, LLC and Magnet Group signed a three-year partnership contract. The agreement allows MAGNET GROUP members to now access all KoKo’s “gold standard” respiratory and pulmonary function testing (PFT) products. MAGNET GROUP members now use the high-quality testing capabilities and features of KoKo’s lung function diagnostics and software for spirometry, diffusion capacity, and PFT. The KoKo Sx 1000 Spirometer, KoKo PX3000, and PX4000 PFT systems deliver accurate, quick, and user-friendly data to help physicians evaluate the respiratory functions of their patients.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Device Type
o By Product Type
o By Application
o By End User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Ganshorn Medizin Electronic GmbH, KoKo, LLC, Koninklijke Philips N.V., Medical Electronic Corp., NDD Medical Technologies, and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Pulmonary Function Testing Market Report Segment
By Device Type
By Product Type
By Application
By End User
Global Pulmonary Function Testing Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/pulmonary-function-testing-market